But I would say, obviously, until that’s in our label, it would all be off-label. And so it would be down to the clinicians to decide what they want to do with their patients.
Mark Twyman: I think what I would add to that, Mike, is the question, will payers decide? I think that what I know is that we have a very strong value proposition for INO-3107. I think we can all kind of look at the results to date from a clinical perspective and know that we have a real potential to address this unmet medical need, both from a patient perspective. It still unsettles me to know that some of these patients experience hundreds of surgeries over a lifetime. And that comes with significant cost burden and just how they go about living their daily lives. But the other sort of point is that physicians aren’t satisfied. I mean, these surgeons are used to sort of treating and resolving an issue that their patient might have.
And that’s just not the case with RRP, and hence the name recurrent respiratory papillomatosis. And I know from having a number of discussions with some of the key KOLs and physicians that are doing a large number of surgeries that they are really looking forward to having this option. And it’s really kind of our job, and it’s the job we’ve already started, to make sure that there’s alignment with what the payers, how the payers sort of value INO-3107, and the fact that physicians are looking for a new option for treating RRP. So I’m feeling really good about where we are, but we’ll have to get to the finish line.
Yi Chen: Will re-dosing be part of the Phase 3 trial?
Jacque Shea: We’re still in discussions with the agency regarding that and haven’t really put the details out there. But it’s certainly, as I said, it’s certainly something that we are thinking about.
Yi Chen: Okay. Thank you.
Operator: Thank you. [Operator Instructions] There are no further questions at this time. Please continue.
Jacque Shea: Thank you. The significant progress we have made in advancing INO-3107 over the past few months means that we are moving closer to providing a potentially life-changing non-surgical treatment option to patients suffering from RRP. I remain incredibly grateful to the patients, patient advocates, trial investigators, and our dedicated team here at Inovio that has enabled us to achieve this. I’m confident that our experienced team is prepared for the next critical steps of development and potential commercialization for INO-3107. And thanks to the corporate strategy we’ve been implementing over the past year, I’m also confident that Inovio now has the key drivers in place for broader long-term success. We have a diversified pipeline focused on candidates with scientific and clinical promise, achievable pathways to market, and strong commercial potential.
We have our proprietary DNA medicines platform and technology, along with a history of strong partnerships to accelerate progress and innovation. And we have the benefit of an incredibly experienced team focused on financial discipline, operational excellence, and motivated by the patients who could someday benefit from the power of DNA medicine. There is much work to be done, but I speak for the entire Inovio team when I say that we are energized by what the future could hold for DNA medicine and patients around the world. With that, thank you again for your attention. Have a great evening, everyone.
Operator: Thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you all for participating. You may all disconnect.
